Announcements Trials
Browse Landscape

Phase

Phase 4 3Phase 2 2Phase 1 1

Status

Active not recruiting 4Recruiting 2

Sponsor Class

OTHER 3NIH 3

Study Type

Interventional 6

Sponsor

Cancer Type

Tumor-Agnostic 1Other hematologic neoplasm 1Gynecologic 1

Conditions

Papillomavirus Infections 2Neoplasms 1Human Papillomavirus-Related Cervical Carcinoma 1Human Papillomavirus-Related Carcinoma 1Hematologic Neoplasms 1

Interventions

Specimen Handling 625pembrolizumab 606Magnetic Resonance Spectroscopy 550Carboplatin 448Cisplatin 396Cyclophosphamide 394Biopsy 371Paclitaxel 323Nivolumab 322Gemcitabine 317Radiotherapy 283Bevacizumab 242Dexamethasone 222fludarabine 213Docetaxel 198durvalumab 194Oxaliplatin 187venetoclax 186atezolizumab 179Fluorouracil 176Rituximab 175Pemetrexed 172Capecitabine 167Radiation 164Doxorubicin 164Radiosurgery 159Ipilimumab 145Etoposide 142Leucovorin 140Lenalidomide 138

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Interventional × Human Papillomavirus Recombinant Vaccine nonavalent × 90 days × Clear all
NCT03036930 2026-05-29

Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients

National Cancer Institute (NCI)

Phase 2 Active not recruiting
51 enrolled 10 charts

Papillomavirus Infections

NCT05237947 2026-05-28

PRISMA

National Cancer Institute (NCI)

Phase 4 Active not recruiting
5,000 enrolled
Gynecologic

Human Papillomavirus-Related Cervical Carcinoma

NCT03023631 2026-05-20

Gardasil 9 Vaccine in Preventing HPV Infection in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

M.D. Anderson Cancer Center

Phase 4 Active not recruiting
48 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT05985681 2026-05-13

Testing RG1-VLP Vaccine to Prevent HPV-related Cancers

National Cancer Institute (NCI)

Phase 1 Recruiting
18 enrolled

Human Papillomavirus-Related Carcinoma

NCT04206813 2026-04-29

An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen

Boston Medical Center

Phase 4 Active not recruiting
352 enrolled

Papillomavirus Infections

NCT06658405 2026-03-18

HPV2

Centre Oscar Lambret

Phase 2 Recruiting
85 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡